ImmuPharma Balance Sheet Health
Financial Health criteria checks 4/6
ImmuPharma has a total shareholder equity of £2.7M and total debt of £0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are £4.1M and £1.4M respectively.
Key information
0%
Debt to equity ratio
UK£0
Debt
| Interest coverage ratio | n/a |
| Cash | UK£1.08m |
| Equity | UK£2.69m |
| Total liabilities | UK£1.37m |
| Total assets | UK£4.06m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 25I's short term assets (£2.2M) exceed its short term liabilities (£1.4M).
Long Term Liabilities: 25I has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: 25I is debt free.
Reducing Debt: 25I has no debt compared to 5 years ago when its debt to equity ratio was 1.3%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 25I has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 25I has less than a year of cash runway if free cash flow continues to grow at historical rates of 14.9% each year.